GlassScriptPhysician profile
Philip Creps
NPI 1649284688
$4,116.25
in general payments reported to CMS, 2019-2025
20 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $148 · 2021: $684 · 2022: $679 · 2023: $534 · 2024: $900 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.81 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.87 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.29 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $549.45 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $358.42 | 2021-2025 | Spravato |
| Almatica Pharma LLC | $305.47 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $255.63 | 2022-2025 | Rexulti |
| Janssen Scientific Affairs, LLC | $228.95 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $76.79 | 2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $67.67 | 2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $62.03 | 2025 | |
| Sunovion Pharmaceuticals INC. | $50.43 | 2019-2021 | |
| Owp Pharmaceuticals, INC. | $45.09 | 2023-2024 | Subvenite, Lamotrigine |
| Tris Pharma INC | $36.71 | 2024 | Dyanavel Xr |
| Corium, LLC | $36.02 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.32 | 2025 | Trintellix |
| Biogen, INC. | $28.42 | 2024 | |
| Axsome Therapeutics, INC. | $27.63 | 2024 | Auvelity |
| Tempus Ai, INC | $23.81 | 2024 | |
| Bausch Health US, LLC | $19.25 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Creps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.